Eloralintide is a 37-amino-acid synthetic peptide in the amylin family, built to mimic a hormone the body already makes [1][7]. Amylin is a 37-amino-acid hormone that the beta cells of the pancreas, the insulin-producing cells, release alongside insulin after a meal [1][6]. The natural hormone slows stomach emptying, dampens glucagon release and promotes satiation, the feeling of having had enough to eat [6][8]. Eloralintide keeps the 37-amino-acid backbone, changes three positions to non-coded amino acids, replaces the natural disulfide bond with a more stable methylene thioacetal bridge, and attaches a 20-carbon fatty diacid through a linker at a lysine residue [1]. That fatty acid lets the peptide ride on albumin, the main protein in blood plasma, which extends its stay in the body and supports once-weekly dosing [1].
Daniel A. Briere and colleagues at Eli Lilly reported the discovery work in 2025, and the paper says eloralintide was made by solid-phase peptide synthesis, a stepwise chemical method [1]. The design goal was selectivity: cagrilintide, the older analog, activates AMY1R, AMY3R and the calcitonin receptor with comparable relative potency, while eloralintide was engineered to favor AMY1R [1]. In human cell assays it activated AMY1R about 12-fold more potently than the calcitonin receptor and 11-fold more potently than AMY3R [1]. The discovery team suggests that less engagement of the calcitonin receptor may support better gastrointestinal tolerability [1]. Cagrilintide is the main comparator in the animal work [1].
The research potential sits in obesity and the conditions that often accompany it: type 2 diabetes and obstructive sleep apnea [16][17][18]. A 48-week phase 2 trial reported mean weight loss of up to 20% against 0.4% with placebo [2], and a 12-week phase 1 study showed weight loss with low rates of gastrointestinal events [3]. As of October 2026, eloralintide remains an investigational drug in phase 3 trials, the large studies that confirm an effect before approval, and it has no approval for human therapeutic use [16][17][18]. The phase 3 ENLIGHTEN program is recruiting in obesity and type 2 diabetes [16][17], with ENLIGHTEN-3 in sleep apnea [18] and ENLIGHTEN-4 in knee osteoarthritis [19]. A separate phase 3 trial, AMPLIFY-1, is scheduled to start in December 2026 with a fixed eloralintide-GLP-2T combination [21]. Antidoping rules also reach it: the WADA 2026 list does not name eloralintide, and its S0 class covers drugs still in clinical development [23].
Key takeaways
- Eloralintide is a 37-amino-acid analog of the hormone amylin, engineered to activate the AMY1R receptor subtype more strongly than the calcitonin receptor [1].
- In a 48-week phase 2 trial in 263 adults, once-weekly eloralintide lowered mean body weight by 9% to 20% depending on the regimen, against 0.4% with placebo, with nausea and fatigue the most common adverse events [2].
- Phase 3 ENLIGHTEN trials in obesity and type 2 diabetes [16][17], sleep apnea [18] and knee osteoarthritis [19] are recruiting, and as of October 2026 the drug has no approval and is not named on the WADA or NCAA lists [16][23][24].
How it works
Selective activation of the AMY1R receptor
Eloralintide works by standing in for amylin at the amylin receptor. A receptor is a protein on a cell surface that a hormone or drug binds to in order to start a signal inside the cell, and an agonist is a molecule that switches it on. The amylin receptor is a pair: the calcitonin receptor, which also responds to the bone hormone calcitonin, joined to a small helper protein called a receptor activity-modifying protein, or RAMP. Three RAMPs make three subtypes, AMY1R, AMY2R and AMY3R, and the paper measures AMY1R and AMY3R against the calcitonin receptor [1].
The subtype matters because the three amylin receptors do not do the same jobs. In human cell lines engineered to carry one receptor at a time, eloralintide activated AMY1R with a half-maximal effective concentration, or EC50, of 23.9 picomolar, against 291.0 picomolar at the calcitonin receptor and 253.8 picomolar at AMY3R [1]. EC50 is the concentration that produces half of the maximum response, so a lower number means a more potent drug. That works out to roughly 12-fold selectivity over the calcitonin receptor and 11-fold over AMY3R. Binding assays gave a similar picture, with about 8-fold higher affinity for AMY1R than for either other receptor, and the peptide was a full agonist at all three [1].
Two caveats keep the numbers in context. The assays ran without albumin, and when 1% human serum albumin was added the potency of lipidated peptides including eloralintide fell, while selectivity over the calcitonin receptor held [1]. Species also differ: in rat cells eloralintide was 45-fold more potent at AMY1R than at the calcitonin receptor but only 3-fold more potent than at AMY3R, so the rat behaves as a broader amylin agonist than the human receptor panel predicts [1].
Appetite, gastric emptying and the brain
Eloralintide is designed to reproduce amylin's effect on meal size and timing. Amylin slows gastric emptying, the rate at which the stomach releases food into the small intestine, suppresses glucagon, a hormone that raises blood glucose, and promotes satiation [6][8]. These actions are central: amylin works on receptors in the brain, including the hindbrain, the lower brain region that helps control meal termination and nausea [6].
The animal data match that picture. In lean rats a single subcutaneous dose of eloralintide reduced food intake and body weight in proportion to dose, and at the top dose tested body weight was 14.9% below baseline four days later [1]. In diet-induced obese rats, a model in which a high-calorie diet produces excess fat, repeated dosing every three days lowered food intake and body weight across a 0.1 to 100 nanomole per kilogram range [1].
The animal work reported feeding and body-composition outcomes, not which brain circuits carry the effect for this molecule. The receptor data come from cell lines, and the feeding data are whole-animal outcomes. A 2026 review of amylin pharmacology discusses how hindbrain and parabrachial circuits may shape nausea, malaise and emesis, and argues that receptor engagement and exposure kinetics may influence whether reduced eating reflects satiation or aversion [6]. That framework fits eloralintide's design, though the discovery paper does not report circuit-level mapping for this peptide.
Albumin binding and the once-weekly profile
A fatty acid tail is what turns a short-lived hormone into a weekly drug. Albumin is the most abundant protein in blood plasma, and a peptide that binds it is held in circulation and released slowly, which flattens its concentration curve. Eloralintide carries a 20-carbon fatty diacid attached through a linker, and that lipid is the part that binds albumin [1].
In the single-dose first-in-human study the peptide was absorbed slowly, with a median time to peak concentration of 72 to 132 hours, and its terminal half-life was 310 to 366 hours, or 12.9 to 15.3 days, across the doses where it could be measured [1]. Half-life is the time it takes for the amount in the body to fall by half. Exposure rose in proportion to dose across the 0.4 to 12 mg range, while peak concentration rose less than proportionally [1].
The contrast with cagrilintide is part of the design story. Cagrilintide has a half-life of 159 to 195 hours, or 6.6 to 8.1 days, in a separate phase 1 study, and the discovery paper says the implications of eloralintide's longer exposure for efficacy and side effects are not yet understood [1]. A longer half-life means steadier levels between doses and a slower decline after treatment stops; it also means that an adverse effect can persist.
Fat mass, lean mass and the quality of weight loss
Weight loss is not only a number, because the tissue lost affects strength and function. Fat mass is stored energy, and lean mass is everything else, mostly muscle, bone, organs and water. In diet-induced obese rats, fat accounted for about 68% to 85% of the weight lost across eloralintide dose groups [1].
The head-to-head comparison sharpened the point. With similar food intake and slightly less total weight loss, rats given eloralintide lost significantly less lean mass than rats given cagrilintide, a difference the authors reported at p = 0.0101 [1]. The discovery paper is careful about what that means: lean mass includes muscle, bone and water, the two drugs may differ for reasons the study did not identify, and the finding comes from rats [1].
Human body-composition data are thinner. A 2026 cardiometabolic review reports that early clinical studies suggest preferential fat mass loss, alongside reductions in pulse rate, blood pressure, inflammatory markers and lipids [4]. The phase 2 abstract reports weight change and adverse events, not body composition, so that description rests on the review rather than on a published body-composition table [2][4]. Preferential fat loss is a hypothesis for the phase 3 program to test, not a settled human result.
Gastrointestinal tolerability and the taste-avoidance signal
The tolerability claim is the most distinctive part of the eloralintide story, and it rests on an animal test with a specific logic. Conditioned taste avoidance is a learned refusal of a flavor that has been paired with a drug; researchers use it as a proxy for aversive signaling, the process that can show up as nausea. A drug that cuts food intake without producing much taste avoidance is more likely to be reducing appetite than causing sickness.
In lean rats, eloralintide and cagrilintide reduced food intake about equally 24 hours after dosing, but eloralintide produced significantly less conditioned taste avoidance 72 hours later [1]. The dose that produced half of the maximum avoidance effect was 8.9 nanomoles per kilogram for eloralintide and 4.2 for cagrilintide, so roughly twice as much eloralintide was needed to reach the same aversion signal [1].
The human data are mixed rather than a clean confirmation. The single-dose first-in-human study found gastrointestinal events in 2 of 36 participants given eloralintide, and the 12-week phase 1 study found diarrhea in 10%, nausea in 8% and vomiting in 4% [1][3]. The 48-week phase 2 trial then reported nausea in up to 64% of one dose group against 14% with placebo [2]. The discovery paper suggests that calcitonin receptor engagement may explain the rat difference between the two drugs, and it says the in vivo selectivity of both molecules still needs work [1].
What has been studied in humans
Human testing of eloralintide began in 2022 [10]. Three studies are published: a single-dose phase 1 study, a 12-week phase 1 study and a 48-week phase 2 trial in 263 adults [1][2][3]. Four completed phase 1 and phase 2 studies have not posted results [12][13][15], including the 367-participant phase 2 trial in type 2 diabetes [14]. Five phase 3 trials are recruiting: ENLIGHTEN-1 and ENLIGHTEN-2 [16][17], ENLIGHTEN-3 and ENLIGHTEN-4 [18][19], and ENLIGHTEN-6 [20]. A phase 2 trial tests whether a treatment works in participants who have the condition, and a phase 3 trial confirms the result at larger scale before a regulator reviews it.
The single-dose first-in-human study randomized 48 healthy participants with a mean body mass index of 27.5, the ratio of weight to height that defines overweight at 25 and obesity at 30 [1]. Participants received a single dose across six cohorts or an inactive placebo. Nine participants given eloralintide reported 16 adverse events, almost all mild; two participants had four gastrointestinal events, including one moderate vomiting episode at the highest dose, and there were no serious adverse events or discontinuations [1]. Four weeks after a single dose, mean weight change was -2.5% and -4.4% in the two highest cohorts, against +0.6% with placebo [1].
The 12-week multiple-dose study enrolled 100 adults with obesity or overweight at three US centers, with a mean body mass index of 32.6 [3]. Five cohorts received weekly eloralintide without dose escalation. Weight loss at week 12 ranged from 2.6% to 11.3% across dose groups, and the most common adverse events were decreased appetite in 19%, headache in 12%, fatigue in 11% and COVID-19 in 11% [3]. Gastrointestinal events were infrequent, with diarrhea in 10%, nausea in 8% and vomiting in 4%, and most events were mild [3].
The phase 2 trial is the efficacy anchor. It randomized 263 adults at 46 US centers, with a mean body weight of 109.1 kilograms and a mean body mass index of 39.1, to placebo or six eloralintide regimens for 48 weeks [2]. Mean weight change was -9%, -12%, -18%, -20%, -20% and -16% across the eloralintide groups, against -0.4% with placebo, so the effect rose with dose and then plateaued [2]. Nausea and fatigue were the most common adverse events, and the authors called the result clinically meaningful and generally well tolerated [2].
An independent network meta-analysis pooled six trials of long-acting amylin therapies and estimated a mean difference of -18.01% for high-dose eloralintide against placebo, with nausea, vomiting and constipation more common with high-dose amylin therapies [9]. That analysis covered 4,642 participants in trials of 12 to 68 weeks, and its authors call the findings preliminary and in need of confirmation [9]. It does not substitute for a head-to-head trial.
The combination program has produced completed studies but no public results. A phase 1 study of eloralintide with GLP-2T in 96 adults with overweight or obesity has completed, a Japanese phase 1 study in 128 participants has completed, and a phase 1 pharmacokinetic study in 188 participants has completed [12][13][15]. As of the registry records reviewed in October 2026, none has posted results. A 367-participant phase 2 trial in adults with obesity or overweight and type 2 diabetes completed in September 2026, also without posted results [14]. That silence is the main gap in the human record at this stage.
The human evidence has clear limits. The longest randomized exposure is 48 weeks, the phase 2 trial enrolled only adults without diabetes, and all three published studies were funded by Eli Lilly, whose employees are authors [1][2][3]. The published eloralintide trials did not compare it with cagrilintide, and the combination trials that include an incretin arm have not posted results [2][14][21]. The phase 2 abstract reports neither a body-composition nor a cardiovascular outcome [2][4]. The phase 3 program is designed to answer the efficacy question at scale, not the mechanism questions.
Doses studied in human trials
As of October 2026, Eloralintide remains investigational, with no approval for human therapeutic use. Regimens below are those reported in the cited human trials.
Once-weekly subcutaneous eloralintide at 1, 3, 6 or 9 mg, or escalation from 6 to 9 mg or 3 to 9 mg, for 48 weeks, against placebo
263 adults aged 18 to 75 with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition, and without type 2 diabetes, at 46 US centers
Once-weekly subcutaneous eloralintide without dose escalation across five multiple-ascending-dose cohorts for 12 weeks, against placebo
100 adults with obesity or overweight at three US centers, mean body mass index 32.6
Single subcutaneous eloralintide doses from 0.04 to 12 mg across six cohorts, against placebo
Cell lines expressing human or rat amylin and calcitonin receptors, rats, monkeys, and 48 healthy participants with a mean body mass index of 27.5
Lab and animal studies
The preclinical program was built to answer two questions: whether eloralintide can be selective at the receptor, and whether that selectivity buys better tolerability. The work combines receptor pharmacology in engineered cell lines with rat studies of feeding, body weight and body composition, plus pharmacokinetics in rats and monkeys [1].
The receptor work used UMUC3 cells engineered to express one human or rat receptor at a time, with cyclic AMP accumulation as the readout of activation [1]. Against human receptors, eloralintide was about 12-fold more potent at AMY1R than at the calcitonin receptor and 11-fold more potent than at AMY3R, and it was a full agonist at all three [1]. Against rat receptors it was 45-fold more potent at AMY1R than at the calcitonin receptor but only 3-fold more potent than at AMY3R, a difference that matters when rat tolerability is used to predict human tolerability [1].
In lean rats, a single subcutaneous dose from 0.1 to 300 nanomoles per kilogram produced dose-proportional reductions in food intake and body weight, with a 14.9% drop in body weight at the top dose four days later [1]. Cagrilintide at the same top dose produced a 14.5% drop, and the two drugs had similar potency at 24 hours [1]. By 96 hours eloralintide had a significantly lower ED50 for food intake, 3.7 against 8.5 nanomoles per kilogram, though the body-weight ED50 difference was not significant [1]. ED50 is the dose that produces half of the maximum effect.
In diet-induced obese rats, repeated dosing every three days from 0.1 to 100 nanomoles per kilogram lowered food intake and body weight, with a 12.3% weight reduction at the top dose on day 13 [1]. Fat mass accounted for about 68% to 85% of the loss across dose groups [1]. In a separate head-to-head study, eloralintide at 100 nanomoles per kilogram and cagrilintide at the same dose produced mean weight changes of -11.1% and -13.3% at day 15, and eloralintide preserved more lean mass, with fat accounting for 80% to 91% of its weight loss against 63% for cagrilintide at two weeks [1].
The taste-avoidance experiment is the behavioral counterpart. Rats were given saccharin, an artificial sweetener, for 40 minutes and then a single dose of peptide; three days later the researchers measured how much they avoided the sweet solution [1]. Food intake fell similarly with both drugs at 24 hours, but eloralintide produced less avoidance, with an ED50 of 8.9 against 4.2 nanomoles per kilogram [1].
Pharmacokinetics in male rats and cynomolgus monkeys showed higher exposure, a longer half-life and flatter concentration curves for eloralintide than for cagrilintide at the doses tested [1]. The limits are substantial. The animal models may not fully replicate human physiology, the rat receptor profile is broader than the human one, and the discovery paper notes that no minimum selectivity threshold defines a biologically meaningful difference [1]. The feeding and body-composition studies were acute or two weeks long, not multi-month studies.
Research in detail
Phase 2, multicenter, double-blind, randomized, placebo-controlled dose-ranging trial · 263 adults aged 18 to 75 with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition, and without type 2 diabetes, at 46 US centers
Mean weight change at 48 weeks was -9%, -12%, -18%, -20%, -20% and -16% across the eloralintide groups against -0.4% with placebo; nausea and fatigue were the most common adverse events.
Evidence scope: Single country, 48 weeks, adults without diabetes, and Eli Lilly funded the trial and employed several authors. Abstract reviewed; full text not read.
Phase 1, randomized, placebo-controlled, participant- and investigator-blinded multiple-ascending-dose trial · 100 adults with obesity or overweight at three US centers, mean body mass index 32.6
Least-squares mean weight reduction ranged from 2.6% to 11.3% at week 12; decreased appetite, headache and fatigue were the most common adverse events, and diarrhea, nausea and vomiting were each reported in 10% or fewer of participants.
Evidence scope: Twelve weeks, no dose escalation, and Eli Lilly funded the study and employed all authors. Abstract and open-access full text reviewed.
Translational discovery program with receptor pharmacology, rat and monkey studies, and a phase 1 single-ascending-dose trial · Cell lines expressing human or rat amylin and calcitonin receptors, rats, monkeys, and 48 healthy participants with a mean body mass index of 27.5
Eloralintide was 12-fold more potent at human AMY1R than at the calcitonin receptor; at week 4 after a single dose, weight change was -2.5% and -4.4% in the two highest cohorts against +0.6% with placebo, and no serious adverse events occurred.
Evidence scope: Small single-dose cohorts, healthy participants rather than an obesity population, and Eli Lilly funded the work and employed all authors. Abstract and open-access full text reviewed.
Phase 2, randomized, double-blind, placebo-controlled, parallel-group trial of eloralintide and GLP-2T alone or in combination · 367 adults with obesity or overweight and type 2 diabetes
The trial completed in September 2026; no results are posted on ClinicalTrials.gov as of October 2026, so the comparison of the combination with either drug alone is not yet public.
Evidence scope: Registry record only; no published results and no peer-reviewed report.
Phase 1, open-label pharmacokinetic and safety study of eloralintide alone and with GLP-2T · 188 adults with overweight or obesity
The study completed in January 2026 and measured exposure of both peptides; no results are posted on ClinicalTrials.gov as of October 2026.
Evidence scope: Registry record only; pharmacokinetic endpoints and no efficacy results.
Phase 3, randomized, placebo-controlled trial (ENLIGHTEN-1) · Estimated 1,980 adults with obesity or overweight and without type 2 diabetes
The trial is recruiting, with a primary endpoint of percent change in body weight and an estimated primary completion in March 2028; no results are available.
Evidence scope: Registry record only; the trial is ongoing and the primary completion date is an estimate.
Phase 3, randomized trial of a fixed eloralintide-GLP-2T combination against each component and placebo (AMPLIFY-1) · Estimated 2,115 adults with obesity and without type 2 diabetes
The trial is not yet recruiting and is scheduled to start in December 2026, with an estimated primary completion in October 2029; no results are available.
Evidence scope: Registry record only; the start date and enrollment are planned rather than actual.
History and where it stands today
Eloralintide moved from first-in-human testing in 2022 to a phase 3 program by the end of 2025.
- 2022The first-in-human phase 1 trial of LY3841136 opens in March 2022, a randomized, placebo-controlled study in healthy and overweight participants that enrolled 148 across its single- and multiple-dose parts [10].
- 2024A phase 2 obesity trial begins at 46 US centers, randomizing 263 adults with obesity or overweight and at least one weight-related condition to weekly eloralintide or placebo for 48 weeks [11].
- October 2025The discovery paper reports the molecule's design, its AMY1R selectivity and the first-in-human results, including mean weight loss of 2.5% and 4.4% four weeks after single doses in the 4 mg and 12 mg cohorts, against +0.6% with placebo [1].
- November 2025The Lancet publishes online the 48-week phase 2 trial, with mean weight loss of 9% to 20% across dose groups against 0.4% with placebo [2].
- December 2025The first phase 3 trial, ENLIGHTEN-2, begins recruiting adults with obesity or overweight and type 2 diabetes, with an estimated 1,035 participants [17].
- January 2026The 12-week phase 1 multiple-dose study is published online, reporting weight loss of 2.6% to 11.3% and gastrointestinal events in 10% or fewer of participants [3].
- February 2026ENLIGHTEN-1 opens in obesity without type 2 diabetes with an estimated 1,980 participants, and ENLIGHTEN-3 and ENLIGHTEN-4 open in obstructive sleep apnea and knee osteoarthritis [16][18][19].
- September 2026A 367-participant phase 2 trial in obesity with type 2 diabetes completes; no results are posted on ClinicalTrials.gov as of October 2026 [14].
- December 2026AMPLIFY-1, a phase 3 trial of the eloralintide-GLP-2T fixed combination against each component and placebo, is scheduled to start with an estimated 2,115 participants [21].
- October 2026Eloralintide remains investigational with no approval for human therapeutic use; WADA's 2026 list does not name it and its S0 class covers drugs in clinical development, while the NCAA page explains the class 6 catch-all [16][23][24].
How it compares with related peptides
Cagrilintide is the main comparator in the eloralintide program. Cagrilintide activates AMY1R, AMY3R and the calcitonin receptor with comparable relative potency, while eloralintide is 8- to 12-fold selective for AMY1R in human assays [1]. The discovery paper notes that cagrilintide at 2.4 mg was associated with nausea in 24% to 31% of adults with overweight or obesity without diabetes in monotherapy trials [1]. Eloralintide is earlier in development, with a 48-week phase 2 trial reporting up to 20% weight loss, and the published trials did not compare the two drugs head to head in humans [1][2]. The rat work suggests eloralintide produces less taste avoidance and preserves more lean mass, but those are animal findings [1].
GLP-1S represents the incretin class that eloralintide is meant to complement. The two work through different receptors, and a 2026 review argues that amylin therapies may separate weight loss from the nausea that limits incretin drugs [6]. The discovery paper points to a 44% nausea rate in a phase 3 trial of GLP-1S in adults with obesity, against gastrointestinal events in 2 of 36 eloralintide participants in its own single-dose study [1]. That comparison crosses studies and doses, so it is a rationale rather than a result. The phase 3 trials will show whether that tolerability signal holds at scale [16].
Side effects and safety signals
The safety record comes from three published trials, the longest 48 weeks, and the main signals are gastrointestinal and constitutional.
- Nausea was the most common adverse event in the 48-week phase 2 trial, reported in 11% to 64% of eloralintide groups against 14% with placebo [2].
- Fatigue ranged from 0% to 46% across the eloralintide groups in the phase 2 trial, against 12% with placebo [2].
- In the 12-week phase 1 study, decreased appetite affected 19%, headache 12% and fatigue 11%, while diarrhea affected 10%, nausea 8% and vomiting 4%; most events were mild and one serious event in an eloralintide cohort was judged unrelated [3].
- In the single-dose first-in-human study, 9 of 36 participants given eloralintide reported 16 adverse events, almost all mild, with vomiting and dyspepsia confined to the highest dose group and no serious adverse events [1].
- A 2026 narrative review describes a distinct adverse-event profile for eloralintide within the amylin class, including fatigue, headache and appetite loss [5].
- Early data reviewed in 2026 suggest a reduction in pulse rate, which contrasts with the heart-rate increase associated with GLP-1 receptor agonists, and no dedicated cardiovascular outcomes trial has tested what that means [4].
- The half-life of 12.9 to 15.3 days means exposure declines slowly after dosing stops, and the discovery paper says the implications of that long exposure for side effects are not yet understood [1].
- The published trials cover at most 48 weeks of randomized exposure, so long-term safety beyond that window is not established [2]. Purity and identity results for research material are tracked in the COA library.
The future: what's next for Eloralintide
The phase 3 ENLIGHTEN program is the main source of coming data. ENLIGHTEN-1 (NCT07321886) is recruiting, with an estimated enrollment of 1,980 adults with obesity or overweight and without type 2 diabetes, and ENLIGHTEN-2 (NCT07282600) is recruiting with an estimated enrollment of 1,035 adults with obesity or overweight and type 2 diabetes, with primary completions estimated for March 2028 and January 2028 [16][17]. ENLIGHTEN-3 (NCT07369011) is testing an estimated 800 adults with obstructive sleep apnea on body weight and the apnea-hypopnea index, the number of apnea and hypopnea events per hour of sleep, with a primary completion estimated for March 2028 [18]. ENLIGHTEN-4 (NCT07353931) is testing an estimated 900 adults with knee osteoarthritis on weight and the WOMAC pain score, a standard questionnaire measure, with a primary completion estimated for March 2028 [19]. ENLIGHTEN-6 (NCT07392190) is enrolling an estimated 900 adults with persistent obesity despite stable incretin therapy, with a primary completion estimated for June 2028 [20].
Combination data are the other front. AMPLIFY-1 (NCT07881432) plans to randomize 2,115 adults with obesity to the fixed eloralintide-GLP-2T combination, either component alone or placebo, starting in December 2026 with a primary completion estimated for October 2029 [21]. A phase 2 trial of eloralintide with macupatide, another Lilly peptide, is active and not recruiting in an estimated 200 adults with obesity or overweight and type 2 diabetes, with a primary completion estimated for March 2027 [22]. The completed 367-participant phase 2 trial in obesity with type 2 diabetes has not reported, and its results will shape how the combination is positioned [14].
The regulatory path has no dates yet. Eloralintide is an investigational drug, and a filing would follow the phase 3 readouts now expected from 2028 onward [16][17]. In sport, WADA's 2026 list does not name the peptide, and S0 covers substances with no government approval for human therapeutic use, including drugs in clinical development [23]. The NCAA's 2026-27 list does not name it either, and class 6 bans substances chemically or pharmacologically related to peptide hormones and growth factors [24].
The indication list is broadening beyond weight. Sleep apnea and knee osteoarthritis are the two new phase 3 indications, and both measure body weight alongside a condition-specific endpoint: the apnea-hypopnea index and the WOMAC pain score [18][19]. The wider question, covered in the new-indications overview, is whether the class can improve conditions that sit downstream of obesity without adding gastrointestinal burden.
- Whether AMY1R selectivity actually produces better gastrointestinal tolerability than cagrilintide in humans is untested; the published trials did not compare the two drugs head to head [1][2].
- Whether the lean-mass advantage seen in rats holds in humans is unknown, and the phase 2 trial did not report body composition [1][2].
- Whether the reduction in pulse rate seen in early data is harmless, beneficial or a liability for adults with cardiovascular disease needs a dedicated outcomes trial [4].
- Whether the phase 3 trials reproduce the 20% weight loss from phase 2, and in which participants, is the central efficacy question [2][16].
- Whether eloralintide adds benefit on top of an incretin drug, rather than duplicating it, will be answered by the combination program [21].